Open in interactive viewer → charts, metric popovers & call review

Turning Point's New CEO Held the Guide, Filed a Second PMTA, and Stopped Talking About the Promo War

Modern Oral is now half the company and still doubling. So why is the EBITDA line falling 41% and the stock 53% off its February high?
TPB · Earnings Call · 2026-11-09

The guide that would not move

David Glazek's first call as CEO opened with the sort of biography that buys patience — fourteen years around the company, four as executive chairman — and then delivered the number that had already cost shareholders 10% on September 21: full-year Modern Oral net sales of $260–270 million, gross sales of $330–350 million, adjusted EBITDA of $70–80 million, all unchanged from the late-September update. Three separate analysts asked the same question in different clothes. Eric Des Lauriers noted the Modern Oral net revenue guide implies Q4 sequentially "from a slight decrease to a slight increase." Ian Zaffino asked whether seasonality or slotting fees explained it. Gerald Pascarelli asked what gets you to the high versus low end of EBITDA. The answer each time was a variation on “nothing is changing in what we're seeing with the Modern Oral business... we don't have a lot of additional transparency since then” — David Glazek, Chief Executive Officer (CEO) · 2026-11-09. That is the tension. This is a company that has made a habit of raising guidance — in May it lifted Modern Oral net sales by roughly $30 million and gross by $60 million on the back of spring chain wins. Now, with Q3 net sales up 103% year-over-year and Modern Oral at 49% of consolidated revenue versus 31% a year ago, the guide sits still. Holding a number after a history of raising it is itself information.

What the new CEO actually added

The genuinely new material on this call was regulatory, not commercial. Glazek revealed the company is running a two-track PMTA process, exploiting FDA guidance issued in May that opened a secondary pathway: “we are prepping a second PMTA submission... We will list U.S. manufacturing in that PMTA submission” — David Glazek, Chief Executive Officer (CEO) · 2026-11-09. The logic is elegant — altering the manufacturing site inside the original filing risks the FDA demanding re-tests on product from a new line, so PMTA 1 stays clean in the queue while PMTA 2 carries Louisville. That reframes the entire U.S. manufacturing timeline. It was never a capex story; it is a queue-position story, which is why management still won't put a date on 2027. It also explains why PMTA submission tops this quarter's keyword set and secondary pathway appears for the first time — the forward-looking language on this call is regulatory and shelf-related, not demand-related. Note the persistence: PMTA 1 and the spring reset both recur, the latter now framed as the window when ALP's newly-won chain conversations convert.

The silence where the promo war used to be

Here is the contrast that matters most. For at least four straight quarters, Turning Point's calls were dominated by competitive promotion. In August 2025: “since the category became competitive... we've seen consistent promotion from one manufacturer to the next quarter-to-quarter” — Graham A. Purdy, Chief Executive Officer · 2025-08-06. In November 2025, Graham Purdy was blunt: “Q3 was a brutal promotional quarter, but not for us” — Graham Purdy, Chief Executive Officer · 2025-11-05 — and predicted it would persist because three balance-sheet-rich majors have no choice but to spend.

I don't anticipate that the landscape will lighten up anytime soon from a promotional standpoint. It's been going on for over a year now. There has been some large company in the space that has been on promotion at some point in time for well over a year now.

Graham Purdy, Chief Executive Officer · 2025-11-05
This quarter, the word promotional barely appears. In its place is a thesis of consolidation: “fewer players, some of the smaller guys getting weeded out, and both FRE and ALP really being surviving brands that make it to the other side of that moat” — David Glazek, Chief Executive Officer (CEO) · 2026-11-09. The keywords corroborate the shift — promotional environment and large competitor, both top-ten themes in 2025Q3, have fallen out of the company's keyword set entirely, while handful of brands and "ubiquitously distributed" enter. That is either a genuine regime change in the nicotine pouch category or the sound of a challenger that has stopped paying to play. The honest read: both. FRE and ALP are now deployed enough that shelf placement substitutes for price promotion, and the 49% revenue mix gives them a reason to prefer the narrative where the war is ending.

The revenue quality question

Gross Modern Oral sales of $94 million against net of $74 million means roughly $20 million of contra revenue in a single quarter — the slotting, fees and trade spend it costs to buy chain shelf space. Management flagged this dynamic a year ago (“as we go out and we get on shelf and we negotiate those deals to get on shelf, that comes at the expense of contra revenue” — Graham Purdy, Chief Executive Officer · 2025-11-05), and it is now the single largest swing factor between the +114% gross and +103% net growth rates. It is also a global theme: tariff refund benefit and related refund language are among the tape's stronger movers this quarter, and Turning Point's own 56% gross margin print is explicitly a normalization story — Q2 was flattered by a tariff refund, which is why the reported 65.5% gross margin in the prior quarter collapsed back to 56.0% at the Stoker's segment level, down 416 basis points year-over-year. The cost of the land grab shows up below the line. Adjusted EBITDA fell 41% year-over-year to $18 million even as revenue rose 27% to $151 million; operating margin sits at 11.7%, against a 22.2% peak in 2025Q3. Free cash flow was $3.5 million for the quarter, and FCF less stock comp swung from negative $30 million in Q1 2026 to positive $24 million in Q2. Meanwhile effective net cash has climbed from about negative $196 million at the end of 2024 to near zero, and the company ended Q3 with $251 million of cash.

What the tape says

Investors have not been rewarded for the growth. TPB is 53% below its February 2026 peak of $142.98 and down 16.3% over the last 90 trading days, sitting 25% under the August high. The 3.2x price-to-revenue multiple is off 27% from the 4.5x 2025Q4 high, and on 159x FCF the stock is priced for a leverage story that has not yet shown up in the cash flow statement. Glazek's answer to that — and the reason to keep watching — is the largest margin pool in tobacco: “billions and billions of dollars of cigarette revenue shifts to these new forms of nicotine consumption” — David Glazek, Chief Executive Officer (CEO) · 2026-11-09. With no golden-goose cannibalization problem, no M&A appetite, and $10 million of opportunistic buyback executed in the quarter, the company is betting its own cash flow on organic share. The swinging variable is whether the "handful of brands" thesis proves right — and whether a category where the pouch business is still drawing new entrants really is culling, or whether the quiet on promotion is simply the quiet of a company that spent its promotional budget on slotting fees instead.